Research of Subacute Combined Degeneration has been linked to Spinal Cord Diseases, Vitamin B 12 Deficiency, Anemia, Anemia, Pernicious, Nerve Degeneration. The study of Subacute Combined Degeneration has been mentioned in research publications which can be found using our bioinformatics tool below. Researched pathways related to Subacute Combined Degeneration include Pathogenesis, Methylation, Transport, Proprioception, Localization. These pathways complement our catalog of research reagents for the study of Subacute Combined Degeneration including antibodies and ELISA kits against TCN2, LAMC2, CSF2, MTR, SCD.
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Subacute Combined Degeneration below!
For more information on how to use Laverne, please read the How to Guide.
We have 1897 products for the study of Subacute Combined Degeneration that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Subacute Combined Degeneration is also known as Lichtheim's Disease, Neuropathy, Subacute Combined Degeneration, Posterolateral Sclerosis, Putnam-dana Syndrome, Subacute Combined Degeneration Of Spinal Cord.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.